Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy.
about
The mTOR signalling pathway in human cancerHER2 expression beyond breast cancer: therapeutic implications for gynecologic malignanciesDifferentiating mTOR inhibitors in renal cell carcinomaClinical evidence of the efficacy of everolimus and its potential in the treatment of breast cancerPI3K pathway inhibitors for the treatment of brain metastases with a focus on HER2+ breast cancerUse of mTOR inhibitors in the treatment of breast cancer: an evaluation of factors that influence patient outcomesHuman epidermal growth factor receptor family-targeted therapies in the treatment of HER2-overexpressing breast cancerTherapeutic targeting of cancers with loss of PTEN function.Strategies to overcome trastuzumab resistance in HER2-overexpressing breast cancers: focus on new data from clinical trials.A phase-1b study of everolimus plus paclitaxel in patients with small-cell lung cancer.A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy.Phase 2 trial of everolimus and carboplatin combination in patients with triple negative metastatic breast cancerERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics.Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer†.Phase I study evaluating the combination of lapatinib (a Her2/Neu and EGFR inhibitor) and everolimus (an mTOR inhibitor) in patients with advanced cancers: South West Oncology Group (SWOG) Study S0528.Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer.Activity of EGFR, mTOR and PI3K inhibitors in an isogenic breast cell line model.The phosphoinositide-3-kinase-Akt-mTOR pathway as a therapeutic target in breast cancerDual human epidermal growth factor receptor 2 blockade for the treatment of HER2-positive breast cancer.The combination of gefitinib and RAD001 inhibits growth of HER2 overexpressing breast cancer cells and tumors irrespective of trastuzumab sensitivityDeregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention.Clinical potential of novel therapeutic targets in breast cancer: CDK4/6, Src, JAK/STAT, PARP, HDAC, and PI3K/AKT/mTOR pathways.Rapamycin and mTOR: a serendipitous discovery and implications for breast cancerTreating breast cancer in the 21st century: emerging biological therapiesGenetically engineered mouse models of PI3K signaling in breast cancer.Current status of anti-human epidermal growth factor receptor 2 therapies: predicting and overcoming herceptin resistanceHER2-positive advanced breast cancer: optimizing patient outcomes and opportunities for drug development.Hormone Therapy plus mTOR Inhibitors in the Treatment of Endometrial Carcinoma.PRKACA mediates resistance to HER2-targeted therapy in breast cancer cells and restores anti-apoptotic signaling.Personalized drug combinations to overcome trastuzumab resistance in HER2-positive breast cancer.Mechanisms of Trastuzumab resistance in ErbB2-driven breast cancer and newer opportunities to overcome therapy resistance.Pharmacologic inhibition of mTOR improves lapatinib sensitivity in HER2-overexpressing breast cancer cells with primary trastuzumab resistance.Pharmacological strategies to overcome HER2 cross-talk and Trastuzumab resistance.Increased signalling of EGFR and IGF1R, and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas.Toward individualized breast cancer therapy: translating biological concepts to the bedside.Negative feedback and adaptive resistance to the targeted therapy of cancer.Mechanisms of Resistance to Trastuzumab and Novel Therapeutic Strategies in HER2-Positive Breast CancerAdvances in first-line treatment for patients with HER-2+ metastatic breast cancer.The Therapeutic Challenge of Targeting HER2 in Endometrial CancerDeciphering the role of insulin-like growth factor-I receptor in trastuzumab resistance.
P2860
Q24627306-83FCB9A3-F4EE-4BF0-BF5E-A778E1C74E2BQ26822730-92D88ABA-7DDC-4597-B2F4-53B31894B8CCQ26860172-C213B8FD-DB26-4E1C-9DD3-BCEE8BAE23E5Q27001170-FE27083D-90DC-492D-A75A-30D005CA84B1Q27006181-FAD226DF-B447-4ED3-9C59-9DFAC6EFCD3CQ27009257-2C87EFD8-94B8-4D98-80E0-61225D4481F3Q27025863-98CF650D-D9A8-4A6E-8303-30AF3CCEEA40Q27852764-F6FCBD15-6DA9-449C-9FF2-457AF48B124CQ30857631-F5BDBE7B-E911-4D50-89C6-7A031021B1B1Q33409908-AF42D834-26E9-42C3-B0E5-895AB8287855Q33410791-F202B9B7-70E5-4F5B-A19C-9DFA7526F64DQ33414349-8E82521C-2DCA-454E-ABE4-4FD2AFFD6104Q33601653-C6E46118-36E6-4970-BCC0-285D2127C03DQ33683126-9D07927D-8B4C-4541-B9B7-3CC6D6825A67Q33810494-AEC4D37A-B70B-46A2-B0CF-2BACAC30F67BQ33840864-E9BF51A5-BF0F-40D8-83B5-8C4CCAA5771EQ33842810-7D44622B-AB9B-4B0D-A1FD-2094C56CA9C0Q33862290-19AF758D-F93E-46C3-8CA0-F5BE112A5548Q34009045-C4D5FD9B-4FAB-458F-9C13-2344365FF894Q34036041-A89B7798-9CE4-4B5A-A432-50700DEEBC83Q34103963-C25961CD-92AE-4C64-AEE3-8B3E6A08177AQ34147910-8F15F634-304E-406D-A4CC-6371983D8784Q34325486-C06F3E91-CA5B-4A56-956C-A4E2414769DAQ34326536-CF73D1F0-80CD-4B45-9AA7-D8C30C5B44E9Q34332175-066D231F-CF94-42D3-AE38-F2B383BD4065Q34355748-ABE354C9-57A5-4D4F-B4CF-CC707F89FB81Q34499609-D71BA822-9B5A-4398-8CB3-E8AC86FC99DAQ34571141-5339048F-36C7-45D8-8B5D-F988FA7E58A0Q34664078-830D134C-828B-4ED5-9FD4-A4700DAE34A2Q34664129-495DA7E2-BB3E-4C77-8E01-C868427B0151Q35624814-E7639F7F-ED66-4DED-88EF-0DC3F8E58F17Q35783451-327D2E9E-B6EE-4684-AF8F-5CFF5AD73D7AQ35803226-08EC8B16-37B4-4EF0-8870-284DCB856B67Q35889941-E14FFAD7-64C8-474F-950E-2AA39E139A8EQ35913199-EF885124-8AB6-45F7-B08C-0FDC3C957452Q35956411-9CC644D0-6FBB-42A7-AF68-3F3C21353EBFQ35977527-9F5590FD-3AD6-4CEE-BBCE-C9D33265C0C2Q35989963-7AD4CB96-C53B-404B-A89D-6F19DB3E7AF2Q36064912-C7BBED51-273A-47E1-8682-D5113DD23A52Q36102124-68655B8C-567C-4613-B686-333251DABA46
P2860
Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Phase I/II study of trastuzuma ...... on trastuzumab-based therapy.
@ast
Phase I/II study of trastuzuma ...... on trastuzumab-based therapy.
@en
type
label
Phase I/II study of trastuzuma ...... on trastuzumab-based therapy.
@ast
Phase I/II study of trastuzuma ...... on trastuzumab-based therapy.
@en
prefLabel
Phase I/II study of trastuzuma ...... on trastuzumab-based therapy.
@ast
Phase I/II study of trastuzuma ...... on trastuzumab-based therapy.
@en
P2093
P2860
P50
P356
P1476
Phase I/II study of trastuzuma ...... d on trastuzumab-based therapy
@en
P2093
Aysegul A Sahin
Daniel J Booser
David W Kindelberger
Eric P Winer
Gabriel N Hortobagyi
Gerburg M Wulf
Ian E Krop
Jeanna Coviello
Julia A Moore
P2860
P304
P356
10.1200/JCO.2010.32.2321
P407
P577
2011-07-05T00:00:00Z